Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
May 11, 2023
-
BUSINESS Opdivo-Yervoy Shows Similar Mortality Rates in Registration Trial and RWD: Ono
May 11, 2023
-
REGULATORY LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
-
BUSINESS Over 40% of Japan Drug Makers Allow Side Jobs, MSD Has Largest 188 Staffers Tapping Option: Poll
May 9, 2023
-
REGULATORY Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
-
BUSINESS Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
May 8, 2023
-
BUSINESS Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
-
REGULATORY Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
-
ACADEMIA Lung Cancer Trial Aborted as 11 Die after Opdivo-Yervoy Therapy: NCC, JCOG
May 1, 2023
-
REGULATORY Japan Approves Mefeego as First Abortion Pill
May 1, 2023
-
REGULATORY Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
-
BUSINESS 374 Chugai Employees Apply for Voluntary Redundancy Program
April 28, 2023
-
ACADEMIA More Japan-Specific Data, Stable Supplies of Pfizer’s Stelues Needed amid Syphilis Surge: Specialist
April 27, 2023
-
BUSINESS Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
April 26, 2023
-
BUSINESS Sumitomo Curbs Shipments of Diabetes Hopeful Twymeeg on More-Than-Expected Demands
April 25, 2023
-
REGULATORY Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
April 24, 2023
-
BUSINESS Drug Makers’ New Grad Hiring in Japan Up 5.8%, Rising for 1st Time since FY2020
April 21, 2023
-
BUSINESS Nippon BI Logs 4% Growth on NHI Price-Based Sales; Jardiance, Ofev as Engines
April 21, 2023
-
ACADEMIA Abortion Pill Is Beneficial as New Option, but Don’t See It as Easy Solution: OB/GYN Association Chair
April 20, 2023
-
REGULATORY Japan to End Priority Review for COVID Drugs and Vaccines after Severity Downgrade: Official
April 20, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…